We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+53.94%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.09B
AUM Growth
+$380M
(+22%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-7.66%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
58
New
9
Increased
13
Reduced
12
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EyePoint Inc
EYPT
|
+$31.7M |
| 2 |
ALX Oncology
ALXO
|
+$24M |
| 3 |
ABVX
Abivax
ABVX
|
+$21.7M |
| 4 |
CRGX
CARGO Therapeutics
CRGX
|
+$20.1M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$69.8M |
| 2 |
Structure Therapeutics
GPCR
|
+$53.3M |
| 3 |
Cabaletta Bio
CABA
|
+$43.8M |
| 4 |
BridgeBio Pharma
BBIO
|
+$39.6M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$36.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$1.56B
| $513M | 24.5% |
8,494,151
+352,051
| +4% | +$18.1M |
|
|
AMAM
2
DELISTED
Ambrx Biopharma Inc
AMAM
| $160M | 7.64% |
11,231,000
+1,307,311
| +13% | +$14.9M |
|
|
3
EyePoint Inc
EYPT
$999M
| $140M | 6.66% |
6,038,235
+2,838,235
| +89% | +$31.7M |
|
|
4
BridgeBio Pharma
BBIO
$16.4B
| $135M | 6.45% |
3,344,179
-1,318,351
| -28% | -$39.6M |
|
|
ACLX
5
DELISTED
Arcellx
ACLX
| $94.3M | 4.51% |
1,700,000
-450,000
| -21% | -$20.3M |
|
|
RYZB
6
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $75.4M | 3.6% |
1,213,478
+31,215
| +3% | +$776K |
|
7
Biomea Fusion
BMEA
$88.2M
| $51.8M | 2.48% |
3,570,872
| – | – |
|
8
Immunovant
IMVT
$7.93B
| $49.1M | 2.34% |
1,165,000
-60,000
| -5% | -$2.21M |
|
|
ALPN
9
DELISTED
Alpine Immune Sciences Inc
ALPN
| $48.6M | 2.32% |
2,550,000
+650,000
| +34% | +$9.03M |
|
10
Pharvaris
PHVS
$2.28B
| $48M | 2.29% |
1,711,460
+350,000
| +26% | +$7.08M |
|
|
11
ALX Oncology
ALXO
$262M
| $46.8M | 2.23% |
3,142,079
+2,530,000
| +413% | +$24M |
|
12
Tarsus Pharmaceuticals
TARS
$2.55B
| $45M | 2.15% |
2,221,422
-400,000
| -15% | -$6.68M |
|
|
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
| $42.5M | 2.03% |
1,800,000
-2,050,000
| -53% | -$36.5M |
|
14
Vaxcyte
PCVX
$7.65B
| $41.8M | 1.99% |
665,000
| – | – |
|
15
Crinetics Pharmaceuticals
CRNX
$8.88B
| $40.9M | 1.95% |
1,150,000
+48,096
| +4% | +$1.47M |
|
|
APLS
16
DELISTED
Apellis Pharmaceuticals
APLS
| $37.4M | 1.79% |
625,000
-1,375,000
| -69% | -$69.8M |
|
|
MRNS
17
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $35.3M | 1.69% |
3,250,000
+625,000
| +24% | +$4.68M |
|
|
AUTL
18
Autolus Therapeutics
AUTL
$389M
| $35.1M | 1.68% |
5,450,000
+5,057,833
| +1,290% | +$19.3M |
|
19
Olema Pharmaceuticals
OLMA
$977M
| $34.5M | 1.65% |
2,456,800
-2,047,964
| -45% | -$27.5M |
|
20
Immuneering
IMRX
$262M
| $30.9M | 1.48% |
4,204,364
| – | – |
|
21
Edgewise Therapeutics
EWTX
$4.28B
| $27.9M | 1.33% |
2,551,989
-394,898
| -13% | -$2.77M |
|
|
JBIO
22
Jade Biosciences
JBIO
$1.18B
| $27.4M | 1.31% |
34,620
-10,000
| -22% | -$5.1M |
|
|
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
| $27.4M | 1.31% |
+1,182,563
| New | +$20.1M |
|
24
Syndax Pharmaceuticals
SNDX
$1.7B
| $25.4M | 1.21% |
+1,175,000
| New | +$18.1M |
|
25
Korro Bio
KRRO
$145M
| $25.4M | 1.21% |
+529,170
| New | +$17.4M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Cormorant Asset Management held 58 positions worth $2.09B, up 22% from $1.71B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Cormorant Asset Management withdrew a net $160M in Q4 2023, closing 10 positions and reducing 12 holdings. Its most notable exit was Structure Therapeutics, an estimated $53.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Abivax worth $22.8M.
- Cormorant Asset Management's largest Q4 2023 buy was Abivax: 2,130,000 shares worth $22.8M.
- Cormorant Asset Management added most to EyePoint Inc in Q4 2023, an estimated $31.7M increase.
- Cormorant Asset Management's biggest Q4 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $69.8M.
- Cormorant Asset Management fully exited Structure Therapeutics in Q4 2023, selling an estimated $53.3M.
- Cormorant Asset Management's ten largest holdings make up 63% of its $2.09B portfolio in Q4 2023.
- Cormorant Asset Management opened 9 new positions and closed 10 in Q4 2023.
- Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.09B.
Based on Cormorant Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.